It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.


Savings support for the journey ahead

With our Co-Pay Savings Program, you may be eligible to pay as little as $0 out-of-pocket, with a maximum benefit of up to $5,000 to be used at any time each year.*


 

$0 co-pay for
eligible patients*
 


 

Maximum benefit of

up to $5,000
annually to be
used at any time

for eligible patients*

Up-front benefit
provides immediate
support

for patients starting
Omnitrope®

Patients are
automatically
re-enrolled

at the start of each
calendar year

Enroll in our Co-Pay Savings Program
CPOmni (1)
Drop Bar@1.5x


Eligible patients may include:

CPLayer_1

Patients with
high deductibles

CPLayer_1

Co-insured
patients

CPLayer_1

Commercially
insured patients

CPLayer_1

Uninsured
patients
 

OmniSource_4c_full colour

Contact us to discuss your insurance options

It’s normal to have questions about the insurance process when starting growth hormone treatment. An OmniSource Case Manager (OCM) is here to help if you have any questions as you navigate the insurance process.

Learn more about OmniSource
CPOmni (2)
CPIcon (7)

Prefer to pay for Omnitrope with cash?

Learn about the Omnitrope Self Pay Program­
Chrome-rail-Thin 1@1.5x


Questions about Omnitrope?

FAQs

To learn more about Omnitrope and our comprehensive patient support services, see our FAQ page for frequently asked questions about Omnitrope.

 

Read FAQs

Contact Us

You can also call our OmniSource team at the number below. We can walk you through the process of getting started with Omnitrope.

Available: Monday – Friday, 8AM – 8PM ET

Phone: 877-456-6794

 

*Omnitrope Co-Pay Savings Program Eligibility: The Omnitrope Co-Pay Savings Program provides up to $5,000 in annual co-pay support for Omnitrope prescriptions. With the Omnitrope Co-pay Savings Program, eligible patients may pay $0 for their co-pay. Eligible patients who are commercially insured may receive co-pay support in the amount of up to $5,000 annually, and patients who are uninsured may receive co-pay support in the amount of up to $417 monthly, with an annual cap of $5,000. Prescription must be for an approved indication. This program is not health insurance. Patients are not eligible if prescriptions are paid, in whole or in part, by any state- or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months. Eligible patients must have a first use of the program by December 31 of the current year. Omnitrope Co-pay Savings Program may not be combined with any other rebate, coupon, or offer. Omnitrope Co-Pay Savings Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

Indications and Important Safety Information

Indications
Omnitrope is a prescription medicine that contains human growth hormone and is used to treat:

  • Children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature
  • Adults with either adult onset or childhood onset GHD

IMPORTANT SAFETY INFORMATION

Who should not take Omnitrope®?

Omnitrope should not be used by children or adults that have:

  • a critical illness caused by certain types of heart or stomach surgery, accidental trauma, or a sudden and severe breathing problem (respiratory failure)
  • Prader-Willi syndrome who are severely overweight or have a history of breathing problems including sleep apnea
  • cancer or other tumors
  • allergies to growth hormone or any of the ingredients in the medicine
  • certain types of eye problems caused by diabetes
  • closed bone growth plates

What should patients tell their healthcare provider before taking Omnitrope?

Patients should tell their healthcare provider about all of their medical conditions, including if they: 

  • have had heart or stomach surgery, trauma, or serious breathing
    problems
  • have or have had cancer or any tumor
  • have diabetes
  • take any prescription and non-prescription medicines, steroids, vitamins, or herbal supplements
  • are pregnant or breastfeeding, or plan to become pregnant or
    breastfeed 

What are the most common side effects of Omnitrope?

  • local reactions at the injection site (such as pain, numbness,
    redness and swelling)
  • headaches
  • swelling associated with fluid retention
  • pain in joints and muscle pain
  • carpal tunnel syndrome
  • tingling and numbness
  • high blood sugar (hyperglycemia/diabetes) and sugar in your urine
    (glucosuria)
  • unusual skin sensations
  • low levels of thyroid hormone (hypothyroidism)

Other possible side effects of Omnitrope are:

  • return of tumor or cancerous growths
  • headaches, changes in vision, nausea or vomiting (these may be
    symptoms of raised pressure in the brain which requires immediate
    medical attention)
  • hip and knee pain or a limp in children, that can be a sign of
    slipped capital femoral epiphysis
  • worsening of pre-existing curvature of the spine in children
    (scoliosis)
  • increased ear infections and ear disorders in children with Turner
    syndrome; check for cardiovascular disorders (hypertension,
    stroke)
  • intense pain and tenderness in the abdomen as consequence of an
    inflammation of the pancreas (pancreatitis)
  • gasping syndrome (decreased rate of breathing) in children from
    high levels of benzyl alcohol (an inactive ingredient)
  • Increased mortality in patients with Prader Willi and acute illness

Please see full Prescribing Information for Omnitrope.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.